摘要
目的观察玻璃体腔内注射康柏西普联合激光光凝治疗缺血型视网膜中央静脉阻塞的短期疗效。方法纳入2015年1月至2017年7月期间在我院接受治疗的缺血型视网膜中央静脉阻塞单眼患者50例/50眼。将患者随机分为对照组(25眼)和观察组(25眼)。对照组给予全视网膜激光光凝治疗,观察组接受玻璃体腔内注射康柏西普联合全视网膜激光光凝治疗。观察和比较两组治疗前及治疗后3个月的患眼视力、黄斑水肿消退和新生血管渗漏面积的变化情况。评估两组患者不良反应情况和重复治疗情况。结果治疗后3个月,观察组中,18例(72.0%)患者视力提高,3例(12.0%)患者视力下降,4例(16.0%)患者视力稳定;对照组中,6例(24.0%)患者视力提高,12例(48.0%)患者视力下降,7例(28.0%)患者视力稳定,观察组视力提高的患者比例明显高于对照组(P<0.05)。治疗后3个月,观察组黄斑中心凹厚度和新生血管渗漏面积均明显低于对照组(P<0.05)。随访期间,观察组中有1例患者1只眼(4.0%)接受重复治疗,明显低于对照组(6只眼,24.0%,P<0.05)。观察组中,有1例患者出现眼压增高,给予局部降眼压治疗后恢复正常。其他患者均未见与药物相关的眼部和全身不良反应发生。结论玻璃体腔内注射康柏西普联合激光光凝治疗缺血型视网膜中央静脉阻塞安全有效,可促进视网膜黄斑水肿的吸收,减少新生血管生成,提高患眼视力。
Objective To evaluate the short-term clinical efficacy of intravitreal injection of conbercept combined with laser photocoagulation in the treatment of ischemic central retinal vein occlusion. Methods A total of 50 patients（50 eyes） with ischemic central retinal vein occlusion, who were treated at our hospital from January 2015 to July 2017, were enrolled in this study. All the patients were randomly divided into the control group（25 eyes） and the observation group（25 eyes）. The patients in control group were treated with laser photocoagulation alone, and the patients in observation group received the intravitreal injection of conbercept combined with laser photocoagulation. The visual acuity, macular edema and the neovascularization leakage area in two groups were observed. And those before treatment and 3 months after treatment were compared. The adverse drug reactions and repeated treatment were evaluated in two groups. Results After treatment in observation group, the visual acuity was improved in 18 patients（72.0%） and decreased in 3 patients（12.0%）, and another 4 patients（16.0%） had stable vision. In control group, there were 6 patients（24.0%） improved visual acuity, 12 patients（48.0%） decreased visual acuity, and 7 patients（28.0%） had stable vision. The statistical results showed that the patient proportion with improved visual acuity in observation group was significantly higher than that in control group（P〈0.05）. After treatment, the central macular thickness and neovascularization leakage area were lower than those in control group（P〈0.05）. Moreover, during the follow-up period, 1 eye（4.0%） in observation group received repeated treatment, which was significantly lower than that in control group（6/24.0%）（P〈0.05）. In addition, 1 patient in observation group was increased intraocular pressure in the 3 d after injection, and returned to normal after local intraocular treatment. No ocular or systemic adverse drug reactions were observed in other
作者
赵东升
蔡克波
ZHAO Dong-sheng;CAI Ke-bo(Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, Chin)
出处
《世界临床药物》
CAS
2018年第6期393-397,共5页
World Clinical Drug
基金
上海交通大学医工交叉研究项目(编号:YG2014MS72)
